Description
Indication & Scope
TRUQAP® Capivasertib Tablets combines use with fulvestrant for adult patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer carrying PIK3CA/AKT1/PTEN gene alterations that progress after prior endocrine therapy.
- Mechanism: Reversible selective pan-AKT kinase inhibitor that blocks AKT downstream oncogenic signaling pathway, inhibits tumor cell proliferation induced by PI3K/AKT pathway mutations and reverses endocrine therapy resistance.
- Drug class: Oral targeted AKT inhibitor, anti-tumor prescription small-molecule medicine.
- Clinical use: Second-line combination targeted therapy for endocrine-resistant mutated advanced breast cancer.
| Generic Name | Capivasertib Tablets |
| Brand Name | TRUQAP |
| Ingredient | Capivasertib Tablets |
| Dosage Form | Tablets |
| Package | 160mg*6 tablets*4 blisters/box; 200mg*6 tablets*4 blisters/box |
| Conditions Treated | Locally advanced and metastatic ER-positive, HER2-negative breast cancer with PIK3CA/AKT1/PTEN genomic alterations |
| Taboos | Severe hypersensitivity to capivasertib or excipients; patients with uncontrolled severe hyperglycemia or type 1 diabetes; pregnant women |
| Place of origin | Gärtunavägen, Södertälje, 152 57, Sweden |
| Prescription type | Prescription-only |
| Storage Conditions | Store at 20°C to 25°C, sealed and protected from moisture and direct sunlight |
| Manufacturer | AstraZeneca UK Limited |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | HJ20250046; HJ20250047 |
| Approval Date | Apr 15, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 400mg twice daily for 4 consecutive days weekly, followed by a 3-day drug-free break throughout each treatment cycle.
Time: Doses are taken 12 hours apart at fixed daily times, combined with scheduled fulvestrant injections.
Instructions for use: Swallow tablets whole without crushing or chewing; can be taken with or without meals. Dose reduction is allowed for grade 2 and above adverse metabolic reactions.
Interaction: Strong CYP3A4 inhibitors increase systemic exposure of capivasertib, while strong CYP3A4 inducers reduce therapeutic efficacy, concomitant use should be avoided.
Side effects: Diarrhea, hyperglycemia, fatigue, nausea, stomatitis, rash, elevated liver enzymes, and decreased appetite.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
Which type of breast cancer does Capivasertib Tablets treat?
It treats ER-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1 or PTEN mutations after endocrine therapy failure.
What is the pharmacological mechanism of Capivasertib Tablets?
It acts as a pan-AKT kinase inhibitor to block abnormal PI3K/AKT oncogenic signaling and reverse endocrine resistance.
What is the unique administration cycle of Capivasertib Tablets?
It is taken twice daily for 4 consecutive days followed by a 3-day drug-free interval in each cycle.
Which drugs should be avoided during Capivasertib Tablets treatment?
Strong CYP3A4 inhibitors and inducers should be avoided to prevent dose fluctuation and efficacy reduction.
TRUQAP® | Capivasertib Tablets | Breast Cancer | DengYueRX
INN: Capivasertib Tablets
Indications: Breast cancer
Dosage Form: Tablets
Strength: 160mg/tablets; 200mg/tablet
